Filing Flows › IGC Pharma (IGC) › Q2 2025
IGC Pharma (IGC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
IGC Pharma (IGC) reported revenue of $328K for the second quarter 2025 (Q2 2025), +21% from a year earlier and -0.6% from the quarter before. Operating margin was -580.8%, net loss $1.6M (487.5% of revenue).
IGC Pharma, Q2 2025: revenue $328K (+21% year over year), operating margin -580.8%, net loss $1.6M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $328K | -0.6% | +21% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$1.6M | — | — |
| Operating cash flow | −$1.4M | — | — |
What changed
Revenue was $328K in Q2 2025, up 21% year over year and down 1% from the previous quarter. White Labeling Services was the largest line at 98% of revenue. White Labeling Services added $71K year over year (up 28%), 127% of the total change. Wellness and Lifestyle declined 71%.
Gross margin was 47.0%, down 13.0 points from a year earlier. Operating costs exceeded revenue by $1.9M, an operating margin of -580.8%. Operating expenses fell 20% while revenue rose 21%. The quarter ended with a net loss of $1.6M, wider than the previous quarter's $1.2M loss.
Operating cash flow was −$1.4M. Non-cash charges added back $141K of depreciation and amortization and $4.7M of share-based compensation. Working capital and other items used $4.6M. Capital expenditures of $8K exceeded it, leaving free cash flow of −$1.4M.
Questions
What was IGC Pharma's revenue in the second quarter 2025?
IGC Pharma (IGC) reported revenue of $328K for the second quarter 2025 (Q2 2025), +21% from a year earlier and -0.6% from the quarter before.
Was IGC Pharma profitable in the second quarter 2025?
Operating loss was $1.9M (-580.8% of revenue) and net loss $1.6M.
Source: IGC Pharma 10-Q on SEC EDGAR.